anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: There is a high morbidity and mortality rate in mechanical trauma (MT)-induced hepatic injury. Currently, the molecular mechanisms underlying liver MT are largely unclear. Exploring the underlying mechanisms and developing safe and effective medicines to alleviate MT-induced hepatic injury is an urgent requirement. The aim of this study was to reveal the role of mitochondria-associated ER membranes (MAMs) in post-traumatic liver injury, and ascertain whether melatonin protects against MT-induced hepatic injury by regulating MAMs.
METHODS: Hepatic mechanical injury was established in Sprague-Dawley rats and primary hepatocytes. A variety of experimental methods were employed to assess the effects of melatonin on hepatic injury, apoptosis, MAMs formation, mitochondrial function and signaling pathways.
RESULTS: Significant increase of IP3R1 expression and MAMs formation were observed in MT-induced hepatic injury. Melatonin treatment at the dose of 30 mg/kg inhibited IP3R1-mediated MAMs and attenuated MT-induced liver injury in vivo. In vitro, primary hepatocytes cultured in 20% trauma serum (TS) for 12 h showed upregulated IP3R1 expression, increased MAMs formation and cell injury, which were suppressed by melatonin (100 μmol/L) treatment. Consequently, melatonin suppressed mitochondrial calcium overload, increased mitochondrial membrane potential and improved mitochondrial function under traumatic condition. Melatonin's inhibitory effects on MAMs formation and mitochondrial calcium overload were blunted when IP3R1 was overexpressed. Mechanistically, melatonin bound to its receptor (MR) and increased the expression of phosphorylated ERK1/2, which interacted with FoxO1 and inhibited the activation of FoxO1 that bound to the IP3R1 promoter to inhibit MAMs formation.
CONCLUSION: Melatonin prevents the formation of MAMs via the MR-ERK1/2-FoxO1-IP3R1 pathway, thereby alleviating the development of MT-induced liver injury. Melatonin-modulated MAMs may be a promising therapeutic therapy for traumatic hepatic injury.
Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
<P>PROBLEM TO BE SOLVED: To provide a method for rapidly producing transparent soap, with which qualities are improved, a production process is simplified and accelerated.  <P>SOLUTION: Transparent cream soap is fused through procedures of pouring and stirring an alkali emulsifying agent to form a cream soap base, adding pure water to the cream soap base, etc. A concentrated alkali solution comprises an alkali amount and pure water. The concentrated alkali solution is poured to a stirring pot, stirred, simultaneously 1/4 of saponifiable natural oils and fats are gradually poured into the concentrated alkali solution to form the alkali emulsifying agent of the first procedure. Further the alkali solution is stirred and simultaneously 3/4 of the saponifiable natural oils and fats and pure water are poured into the pot to form the cream soap base of the second procedure. Finally, the cream soap base is transferred to a vacuum tank, deaerated in vacuum and pure water is successively and slowly poured into the vacuum tank in a vacuum state and stirred to form the transparent cream soap.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
In patients with haematological diseases regular blood count analyses are necessary. In haematology, capillary blood count analyses became established in routine diagnostics. The method and procedure of capillary blood sampling is well accepted by both the patients and the medical personal for a long time. However, only venous values are generally accepted in clinical routine. It is important to know whether or how capillary blood gives discrepant results for the various parameters. Values for therapeutic decisions, e.g. transfusion, are only known for venous values. So far, there are only deficient data available. Therefore, the aim of this study is (i) to compare capillary blood count parameters with the corresponding venous samples to verify the hypothesis that capillary and venous blood count parameters are equivalent, (ii) to include an adequate large number of adult haematological patients (with low and high values) and healthy adults, (iii) to obtain difference values for conversation of measured capillary values into the corresponding venous values.
Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
Participants will receive placebo for remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w for 24 weeks. From Week 24 to Week 52 participants will receive remibrutinib 25 mg b.i.d. and placebo for omalizumab q4w.
Whey protein will come in powder form and will consist of 20g of protein, and 25.3g of product. We will use Optimum Nutrition Double Chocolate Whey Protein Isolate.
PURPOSE:To obtain the titled hormone having an activity of survival promotion of animal cells, by extracting the pituitary body and brain of various animals with a neutral - acidic aqueous solution, and subjecting the resultant active fraction containing active substances to the chromatography or gel filtration treatment. CONSTITUTION:A pituitary hormone hepatotropin having the following physico- chemical properties: Molecular weight: 9,000 1,000 (by the gel filtration method). Isoelectric point: 4.5-4.8. Thermal stability: Stable to heat, acids and 7M urea. Inactivated with trypsin and unstable to alkalis and hydrogen peroxide. The aimed pituitary hormone hapatotropin is obtained by extracting the pituitary body and brain of various animals, e.g. cattle or pigs, with a neutral - acidic aqueous solvent, e.g. a physiological saline solution, and subjecting the resultant active fraction containing active substances capable of promoting the survival of animal cells to any one of the chromatography, e.g. ion exchange chromatography, or gel filtration or a combination thereof.
The invention relates to blood lipid-lowering active fractions of forsythia suspensa and a preparation method and use of the same. The active fractions are ethyl acetate fractions obtained by concentrating an extract which is extracted from forsythia suspensa leaves by acetone and water. The compound of phillygenin prepared by the invention and the active fractions, namely the ethyl acetate fractions, at which the phillygenin is positioned have good antioxidant activity in vitro. In-vivo experiments show that the ethyl acetate fractions and the phillygenin can lower total cholesterols and low-density lipoprotein cholesterin in the blood serum of a mouse with hyperlipidemia and can lower blood lipid level by an oxidative approach (raising superoxide dismutase SOD and lowering malonydialdehyde MDA). In addition, the ethyl acetate fractions have a better effect of reducing the total cholesterols in the blood serum of the mouse than the phillygenin and cassia seed blood lipid-lowering tablets. The ethyl acetate fractions of the forsythia suspensa leaves can be further developed to play a role in the multi- target co-prevention and treatment of hyperlipidemia and other diseases and have a good application prospect.
There are described compounds of the formula:       wherein R1 is hydrogen, lower alkyl or lower alkenyl R2 is hydrogen, lower alkyl or halogen, R3 is imidazolyl or pyridyl, each of which may have suitable substituent(s), and R4 is hydrogen, lower alkyl, lower alkenyl or hydroxy(lower)alkyl and R5 is hydrogen, hydroxy or acyloxy, or R4 and R5 are linked together to form an additional bond, and pharmaceutically acceptable salts thereof.  The compounds are useful as 5-HT antagonists for treating or preventing central nervous system (CNS) disorders such as psychosis (e.g. schizophrenia, mania, etc.) anxiety, and depression; pains or aches such as headaches (e.g. migraine, cluster headaches, vascular headaches, etc.) and neuralgia (e.g. trigeminal neuralgia, etc.); gastro-intestinal disorders such as symptoms of gastro-intestinal dysfunction such as occur with, for example, dyspepsia, peptic ulcer, reflux oesophagitis and flatulence, and irritable bowel syndrome (IBS); nausea or vomiting, each of which may be associated with cancer therapy; motion sickness; and the like in human being or animals, particularly nausea and vomiting. The preparation of the compounds, pharmaceutical compositions containing them and the use thereof as medicaments are also described.
NEW MATERIAL:A substance originated from a monoclonal antibody and having non-specific activity of the monoclonal antibody in spite of the complete loss of the specific antibody activity characteristic of the monoclonal antibody to be used in immunoassay. USE:Elimination or suppression of non-specific reaction in immunoassay using a monoclonal antibody. PREPARATION:The objective monoclonal antibody-originated substance for suppressing non-specific reaction can be prepared e.g. by fusing a spleen cell of Balb/c mouse immunized with an antigen (e.g. lowly differentiated human adenocarcinoma) with a mouse myeloma cell, screening and cloning the fused cell, diluting the prepared monoclonal antibody solution with 0.05M phosphate-buffered sodium chloride solution and heating the diluted solution at 60 deg.C for 120min. A determination object can be quantitatively determined in high sensitivity while suppressing non-specific reaction by an enzyme immunoassay by supporting immobilized monoclonal antibody on beads and adding and reacting the beads and the monoclonal antibody-originated substance to a specimen solution, thereby performing non-specific reaction.
Background: Contemporarily, transabdominal preperitoneal repair (TAPP) procedure in inguinal hernia treatment is counted among the routine minimal invasive general surgery practices. Increased patient's comfort, namely less postoperative pain, is considered to be its greatest advantage. However, pain following surgery can still be an important problem. Port site local anesthetic injection (PSLAI), iliohypogastric-/ilioinguinal nerve block (IINB), and preperitoneal local anesthetic spraying (PLAS) are relatively new techniques with sparse data to address this issue. Therefore, we conducted this prospective study to evaluate these three methods in patients who underwent TAPP for inguinal hernia repair. Methods: A total of 99 patients were enrolled and randomized equally into three groups. Every patient received a patient-controlled analgesia (PCA) device. PCA usage, total analgesic demands, and numerical rating scale values were recorded at 2, 6, 12, and 24 hours postoperatively (p.o). Results: Patients' demographic data (age, gender, BMI) did not reveal any significant difference between groups (P > .05). Procedure duration was found to be significantly longer in IINB group compared with others (p < .05). Number of PCA usages, total analgesic demand, additional analgesic requirement did not differ significantly between groups at 24-hour p.o (P > .05). PLAS group was found to have less average NSR score compared with other groups at 24 hours p.o (p < .05). Conclusions: All three procedures show promising outcomes with PLAS technique appearing to be slightly superior in terms of pain management in the immediate postoperative period. However, to reach a conclusion more randomized controlled trials covering various aspects and techniques of minimal invasive approach to inguinal hernia repair should be published.
OBJECTIVES: This study aimed to investigate the value of contrast-enhanced ultrasound (CEUS) and superb microvascular imaging (SMI) in evaluating angiogenesis in carotid artery plaques and prognosis in stroke patients.
METHODS: Sixty-one patients with carotid atherosclerotic plaques were selected. All patients received conventional ultrasound, CEUS, and SMI examination, including 32 patients with cerebral infarction and 29 patients without cerebral infarction. The results of CEUS and SMI neovascularization of patients were graded 0, 1, and 2 points according to the image characteristics. The consistency between SMI results and CEUS results was evaluated, and the differences in neovascularization in carotid plaques between patients with cerebral infarction and those without cerebral infarction were compared.
RESULTS: SMI showed that the neovascularization score in plaque was 0 point in 13 cases, 1 point in 24 cases, and 2 points in 24 cases. There were no significant differences in age, sex, plaque size, or echo between the two groups. There was no significant difference between the SMI and CEUS results, P > .05. The CEUS neovascularization grade of patients with cerebral infarction had a higher score, which was significantly different from that of patients without cerebral infarction, P < .05. The SMI neovascularization grade of patients with cerebral infarction had a higher score, which was significantly different from that of patients without cerebral infarction, P < .05.
CONCLUSION: SMI can show neovascularization in plaques, with a significantly higher grade of neovascularization in those of patients with cerebral infarction than in those without cerebral infarction.
Adult participants receive highest single dose of 20 mg/kg IV of L9LS intravenously. Once subjects reach day 7 post-administration without safety concerns dosing begins for pediatric subjects dose escalation arm 1.
Patients included in this study have KS, which is a type of cancer that occurs in nearly 20 percent of patients with AIDS. AIDS patients with extensive KS require treatment with effective cytotoxic (anti-cancer) agents to reduce the tumor size and with antiretroviral agents such as AZT to prevent or ameliorate the development of opportunistic infections. Due to the significant toxic effect of both cytotoxic and antiviral agents on the bone marrow where new blood cells are generated, the combination of these agents is expected to result in complications such as granulocytopenia (very low granulocyte counts). Hematopoietic growth factors such as GM-CSF may reduce the severity and duration of marrow suppression. This may improve survival. Clinical trials of GM-CSF in HIV infected individuals with or without granulocytopenia have shown that the progenitor cells (early blood cells) are responsive to GM-CSF.

AMENDED 910222 Due to continued concerns about GM-CSF toxicities seen in the 5 mcg/kg GM-CSF with 20 mg/m2 adriamycin/BV/AZT cohort, the GM-CSF dose in this study has been reduced while the adriamycin dose escalation will continue.

AMENDED 900430 Dosages for AZT and GM-CSF changed to reflect ongoing results. Original design: Patients receive the combination of AZT, antineoplastic chemotherapy, and GM-CSF in groups of three patients each. The first group receives baseline doses, and if the treatment is well tolerated, the subsequent groups of patients receive higher doses of the chemotherapy, in which the dose of doxorubicin is increased while bleomycin, vincristine, and AZT doses remain fixed throughout the study. The dose of all drugs remains fixed for a given patient. The anticancer drugs are given intravenously every 2 weeks. AZT is given every 4 hours by mouth. GM-CSF is self-injected subcutaneously every day from day 2 - day 12 of each treatment cycle. Patients repeat the chemotherapy every 2 weeks, for a maximum of seven cycles, with AZT being given continuously. When the maximum tolerated dose (MTD) of chemotherapy combined with GM-CSF is determined, the next phase of the study begins. Again the dose of chemotherapy is increased in groups of patients, but the every-day dose of GM-CSF is increased. Again, these chemotherapy cycles are repeated every 2 weeks up to a maximum of seven cycles. Patients receive physician examination and laboratory tests every week during the study and again at 4 weeks after the study. AMENDED: Dosages for AZT and GM-CSF have been changed to reflect ongoing results.
Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
Glyburide 

The decrease of glyburide in the serum of normal healthy individuals is biphasic; the terminal half-life is about 10 hours. The major metabolite of glyburide is the 4-trans-hydroxy derivative. A second metabolite, the 3-cis-hydroxy derivative, also occurs. These metabolites probably contribute no significant hypoglycemic action in humans since they are only weakly active (1/400 and 1/40 as active, respectively, as glyburide) in rabbits. Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route. This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.
The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
The role of Vascular Endothelial Growth Factor (VEGF) in the pathogenesis of neovascular diseases like choroidal neovascularization (CNV) and proliferative diabetic retinopathy has been demonstrated in a series of publications. Therefore intravitreally applied VEGF antagonists have been used in the treatment of CNV in age-related macular degeneration (AMD) and diabetic cases. Three anti-VEGFs are available: Macugen® (Pegaptanib), Avastin® (Bevacizumab) and Lucentis® (Ranibizmab). Pegaptanib sodium is an aptamer designed to bind the VEGF 165 isoform with high affinity. Bevacizumab is a humanized monoclonal antibody to VEGF designed for intravenous administration and approved for the treatment of colorectal cancer. Ranibizumab is an anti-body binding site fragment that is derived from the same anti-VEGF antibody as bevacizumab. The decrease of retinal thickness measured in the OCT provides information concerning the amount of intraretinal fluid accumulation and therefore for the activity of a neovascular lesion. It has been proven that the aqueous humor levels of VEGF of eyes with CNV are significantly higher than those of eyes without ocular or systemic diseases. The retinal thickness and the VEGF concentration in the aqueous humor should give a good correlation to the anti vasogenic effect of the intravitreal treatment. In this study bevacizumab and pegaptanib as monotherapy should be compared with a combined therapy of bevacizumab applied first with pegaptanib used for retreatment. The benefit of this combined therapy should be that an initial blockage of all VEGF isoforms is necessary whereas for retreatment the blockage of the most important isoform in the pathogenesis of CNV is sufficient and the normal function of the retinal pigment epithelium and the choriocapillaris is not affected.
BACKGROUND: Readmission rates following ileostomy formation are high. Dehydration and consecutive renal failure are common causes of readmission, potentially pronounced by drugs affecting the homeostasis. The aim of the study was to assess the risk of dehydration after ileostomy formation in patients treated with angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB) or diuretics.
METHOD: This nationwide population-based cohort study used data derived from the Colorectal Cancer Data Base of several Swedish healthcare registers. The study included all patients operated on with elective anterior resection and temporary ileostomy for rectal cancer clinically staged I-III in Sweden in 2007-2016. Exposure was at least two dispensations of ACEI, ARB or diuretics within 1 year prior to surgery. Outcome was 90-day readmission due to dehydration including acute renal failure.
RESULTS: In total, 3252 patients were included with 1173 (36.1%) exposed to ACEI, ARB or diuretics. The cumulative incidence for 90-day readmission due to dehydration was 29.0% (151 of 520) for exposed versus 13.8% (98 of 712) for unexposed. The proportion of readmissions due to any reason was 44.3% (520 of 1173) for exposed compared to 34.2% (712 of 2079) for unexposed. The incidence rate ratio for readmission due to dehydration was 2.83 (95% c.i. 2.21 to 3.63, P < 0.001). The hazard rate ratio was 2.45 (95% c.i. 1.83 to 3.27, P < 0.001) after adjusting for age, gender and comorbidity.
CONCLUSION: Medication with ACEI, ARB or diuretics defines a vulnerable patient group with increased risk of readmission due to dehydration after ileostomy formation.
BACKGROUND AND PURPOSE: Despite thiamine deficiency being a lesser-known entity in modern times, beriberi in various forms, including thiamine deficiency-related neuropathy, remains endemic in Kashmir due to the consumption of polished rice as a staple food. This observational study investigates cases of peripheral neuropathy of unknown etiology and their potential responsiveness to thiamine administration.
METHODS: This prospective study enrolled adult patients presenting to the emergency department with weakness consistent with thiamine deficiency-related neuropathy and conducted a therapeutic challenge with thiamine on 41 patients. Response to thiamine therapy was monitored based on subjective and objective improvements in weakness and power. Patients were divided into thiamine responders (n = 25) and nonresponders (n = 16) based on their response to thiamine therapy and nerve conduction studies.
RESULTS: Most of the baseline characteristics were similar between responders and nonresponders, except the responders exhibited lower thiamine levels and higher partial pressure of oxygen and lactate levels compared to nonresponders. All patients had a history of consuming polished rice and traditional salt tea. Although weakness in the lower limbs was present in both groups, nonresponders were more likely to exhibit weakness in all four limbs. Clinical improvement was observed within 24 h, but proximal muscle weakness persisted for an extended period of time.
CONCLUSIONS: Thiamine deficiency-related neuropathy presents with predominant lower limb weakness, exacerbated by vomiting, poor food intake, psychiatric illness, and pregnancy. Thiamine challenge should be followed by observation of clinical and biochemical response.
PURPOSE:To obtain an external anti-inflammatory preparation having antirheumatic action, containing evodiamine extracted from a crude drug, evodia fruit, as an effective component and excellent in therapeutic effect and being highly safe at the same time. CONSTITUTION:The external anti-inflammatory preparation contains, as an effective component, evodiamine obtained from an essence extracted from evodia fruit with alcohol used as a medicated bath agent. An evodiamine content in the external preparation is preferably around 10-50mg/g. The external anti- inflammatory preparation is effective for various inflammations such as chronic arthritis, chronic rheumatism, etc. As the effective component is the extract of evodia fruit which has been used as an effective medicated bath agent for neuralgia, rheumatism, etc., it is able to safely administer without fear of toxicity. Evodiamine is obtained as follows. For example, evodia fruits are extracted with methanol to obtain extract A, which is suspended in ammonia water and extracted with chloroform. A chloroform soluble part is extracted with 5%, hydrochloric acid aqueous solution and a water layer is separated. It is further suspended in ammonia water and extracted with chloroform.